Home/Pipeline/GCS003

GCS003

Not disclosed

DiscoveryActive

Key Facts

Indication

Not disclosed

Phase

Discovery

Status

Active

Company

Glen Clova Scientific

About Glen Clova Scientific

Glen Clova Scientific is a private, preclinical-stage biotech leveraging a proprietary Virus-Like Particle (VLP) platform to develop therapeutic vaccines. Its technology is designed to induce natural antibody responses with drastically lower dosing requirements and cost of goods compared to conventional biologics, targeting improved accessibility in both human and veterinary medicine. The lead program, GCS001 for senile pruritus, is slated to enter clinical trials in 2026. The company operates from Dundee, UK, and appears to be pre-revenue, focusing on R&D and potential partnerships.

View full company profile

Therapeutic Areas

Inflammatory Diseases Dermatology Veterinary Medicine

Other Not disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active